- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT03734029
Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice voor HER2-low borstkanker die zich heeft verspreid of niet chirurgisch kan worden verwijderd [DESTINY-Breast04]
Een multicenter, gerandomiseerde, open-label, actief gecontroleerde fase 3-studie van DS-8201a, een anti-HER2-antilichaam-geneesmiddelconjugaat (ADC), versus behandeling naar keuze van de arts voor proefpersonen met HER2-lage, inoperabele en/of gemetastaseerde borstkanker
This study will compare DS-8201a to physician choice standard treatment.
Participants must have HER2-low breast cancer that has been treated before.
Participants' cancer:
- Cannot be removed by an operation
- Has spread to other parts of the body
Studie Overzicht
Toestand
Conditie
Gedetailleerde beschrijving
This is a randomized, 2-arm, Phase 3, open-label, multicenter study to compare the safety and efficacy of trastuzumab deruxtecan versus the physician's choice (2:1) in HER2-low, unresectable and/or metastatic breast cancer participants.
The Sponsor proposes to define a new HER2-low population in this trial including tumors with IHC 1+ and IHC 2+/ISH- HER2 expression.
Studietype
Inschrijving (Werkelijk)
Fase
- Fase 3
Contacten en locaties
Studie Locaties
-
-
-
Brussels, België, 1000
- Institut Jules Bordet
-
Brussels, België, 1090
- Universitair Ziekenhuis Brussel
-
Brussels, België, 1200
- Cliniques Universitaires Saint-Luc
-
Leuven, België, 3000
- UZ Leuven
-
Loverval, België, 6280
- Grand Hôpital de Charleroi
-
Namur, België, 5000
- CHU UCL Namur
-
Tournai, België, 7500
- Centre Hospitalier Wallonie picarde - Site IMC
-
-
-
-
Alberta
-
Calgary, Alberta, Canada, T2N4N2
- Tom Baker Cancer Center
-
-
Ontario
-
Toronto, Ontario, Canada, M4N 3M5
- Toronto Sunnybrook Hospital
-
-
Quebec
-
Montreal, Quebec, Canada, H2W 1S6
- McGill University - Dept. Oncology Clinical Research Program
-
-
-
-
Anhui
-
Hefei, Anhui, China, 230001
- Anhui Provincial Hospital
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, China, 100853
- Chinese PLA General Hospital
-
Beijing, Beijing Municipality, China, 100021
- Cancer Hospital Chinese Academy of Medical Sciences
-
-
Fujian
-
Fuzhou, Fujian, China, 350025
- Fuzhou General Hospital of Nanjing Military Area Command of Chinese PLA
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510120
- Sun Yat-sen Memorial hospital, Sun Yat-sen University
-
-
Heilongjiang
-
Harbin, Heilongjiang, China, 150081
- Harbin Medical University Cancer Hospital
-
-
Hubei
-
Wuhan, Hubei, China, 430079
- Hubei Cancer Hospital
-
-
Jiangsu
-
Nanjing, Jiangsu, China, 210008
- The Affiliated Drum Tower Hospital of Nanjing University
-
-
Jilin
-
Changchun, Jilin, China, 130000
- The First Hospital of Jilin University
-
Changchun, Jilin, China, 130012
- Jilin Cancer Hospital
-
-
Liaoning
-
Shenyang, Liaoning, China, 110042
- Liaoning Cancer Hospital & Institute
-
-
Ningxia Hui
-
Yinchuan, Ningxia Hui, China, 750004
- General Hospital of Ningxia Medical University
-
-
Shandong
-
Linyi, Shandong, China, 276001
- Linyi Cancer Hospital
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, China, 200080
- Shanghai General Hospital
-
Shanghai, Shanghai Municipality, China, 20032
- Fudan University Shanghai Cancer Center
-
-
Sichuan
-
Chengdu, Sichuan, China, 610041
- West China Hospital, Sichuan University
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310022
- Zhejiang Cancer Hospital
-
Hangzhou, Zhejiang, China, 310016
- Sir Run Run Shaw Hospital, Zhejiang University, School of Medicine
-
-
-
-
Baden-Wurttemberg
-
Heidelberg, Baden-Wurttemberg, Duitsland, 69120
- Universitaetsklinikum Heidelberg
-
-
Bavaria
-
Munich, Bavaria, Duitsland, 81377
- Klinikum der Universitaet Muenchen - Campus Grosshardern
-
-
-
-
-
Paris, Frankrijk, 75020
- Hopital Tenon
-
Paris, Frankrijk, 75005
- Institut Curie - site de Paris
-
-
Bouches-du-Rhône
-
Marseille, Bouches-du-Rhône, Frankrijk, 13009
- Institut Paoli Calmettes
-
-
Calvados
-
Caen, Calvados, Frankrijk, 14076
- Centre François Baclesse
-
-
Cotes d'Armor
-
Plérin, Cotes d'Armor, Frankrijk, 22190
- CARIO - Centre Armoricain de Radiothérapie, Imagerie médicale et Oncologie
-
-
Finistere
-
Brest, Finistere, Frankrijk, 29609
- CHU Brest - Hôpital Morvan
-
-
Gironde
-
Bordeaux, Gironde, Frankrijk, 33076
- Institut Bergonié
-
-
Herault
-
Montpellier, Herault, Frankrijk, 34070
- Clinique Clementville
-
Montpellier, Herault, Frankrijk, 34298
- Institut Régional du Cancer de Montpellier
-
-
Ille Et Vilaine
-
Rennes, Ille Et Vilaine, Frankrijk, 35042
- CRLCC Eugene Marquis
-
-
Loire Atlantique
-
Saint-Herblain, Loire Atlantique, Frankrijk, 44805
- ICO - Site René Gauducheau
-
-
Loiret
-
Le Puy-en-Velay, Loiret, Frankrijk, 43012
- Centre Hospitalier Emile Roux
-
-
Maine Et Loire
-
Angers, Maine Et Loire, Frankrijk, 49055
- ICO - Site Paul Papin
-
-
Nord
-
Valenciennes, Nord, Frankrijk, 59322
- Centre Hospitalier Valenciennes
-
-
Paris
-
Paris, Paris, Frankrijk, 75475
- Hôpital Saint-Louis - Paris
-
-
Sarthe
-
Le Mans, Sarthe, Frankrijk, 72015
- Clinique Victor Hugo - Centre Jean Bernard
-
-
Vaculuse
-
Avignon, Vaculuse, Frankrijk, 84918
- Institut Sainte Catherine
-
-
Val De Marne
-
Saint-Mandé, Val De Marne, Frankrijk, 94160
- Hôpital d'Instruction des Armees Begin*
-
Villejuif, Val De Marne, Frankrijk, 94805
- Institut Gustave Roussy
-
-
-
-
-
Athens, Griekenland, 15125
- Athens Medical Center
-
Athens, Griekenland, 11528
- General Hospital of Athens "Alexandra"
-
Athens, Griekenland, 14564
- General Oncology Hospital of Kifissia " Agioi Anargyroi"
-
Heraklion, Griekenland, 71110
- University General Hospital of Heraklion
-
Larissa, Griekenland, 41110
- University General Hospital of Larissa
-
Thessaloniki, Griekenland, 54622
- Bioclinic Thessaloniki
-
Thessaloniki, Griekenland, 54645
- Euromedica General Clinic Thessaloniki
-
Thessaloniki, Griekenland, 56429
- General Hospital Papageorgiou
-
Thessaloniki, Griekenland, 57001
- Interbalkan Hospital of Thessaloniki
-
-
-
-
-
Budapest, Hongarije, 1097
- Del-pesti Centrumkorhaz - Orszagos Hematologiai es Infektologiai Intezet
-
Budapest, Hongarije, 1122
- Orszagos Onkologiai Intezet
-
Debrecen, Hongarije, 4032
- Debreceni Egyetem
-
Gyula, Hongarije, 5700
- Bekes Megyei Kozponti Korhaz Pandy Kalman Tagkorhaza
-
Nyíregyháza, Hongarije, 4400
- SzSzB Megyei Korhazak es Egyetemi Oktatokorhaz
-
Szolnok, Hongarije, 5004
- Jasz-Nagykun-Szolnok Megyei Hetenyi Geza Korhaz-Rendelointezet
-
-
-
-
-
Haifa, Israël, 3109601
- Rambam Health Care Center
-
Jerusalem, Israël, 9103102
- Shaare Zedek Medical Center
-
Jerusalem, Israël, 9112001
- Hadassah University Hospital - Ein Kerem
-
Petah Tikva, Israël, 49100
- Rabin Medical Center-Beilinson Campus
-
Ramat Gan, Israël, 52363
- Chaim Sheba Medical Center
-
Rehovot, Israël, 7610001
- Kaplan Medical Center
-
Safed, Israël, 13100
- Ziv Medical Center
-
Tel Aviv, Israël, 6423906
- Tel Aviv Sourasky Medical Center
-
-
-
-
-
Bologna, Italië, 40138
- Azienda Ospedaliera Universitaria Policlinico Sant'Orsola Malpighi
-
Brescia, Italië, 25100
- Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia (Presidio Spedali Civili)
-
Catania, Italië, 95125
- Azienda Ospedaliera Univ. Policlinico Gaspare Rodolico
-
Catanzaro, Italië, 88100
- Azienda Ospedaliero Universitaria Mater Domini-Campus Universitario
-
Milan, Italië, 20141
- IEO Istituto Europeo di Oncologia
-
Naples, Italië, 80131
- Istituto Nazionale Tumori Fondazione G. Pascale
-
Rimini, Italië, 47923
- Ospedale degli Infermi
-
Roma, Italië, 00168
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
-
Roma, Italië, 00133
- Azienda Ospedaliera Universitaria Policlinico Tor Vergata
-
-
Lecce
-
Tricase, Lecce, Italië, 73039
- Azienda Ospedaliera Card. G. Panico
-
-
Milano
-
Monza, Milano, Italië, 20900
- Azienda Socio Sanitaria Territoriale di Monza (Presidio San Gerardo)
-
Rozzano, Milano, Italië, 20089
- Istituto Clinico Humanitas
-
-
Verona
-
Negrar, Verona, Italië, 37024
- Ospedale Sacro Cuore Don Calabria
-
-
-
-
Aichi-ken
-
Nagoya, Aichi-ken, Japan, 464-8681
- Aichi Cancer Center Hospital
-
-
Chiba
-
Kashiwa-shi, Chiba, Japan, 277-8577
- National Cancer Center Hospital East
-
-
Ehime
-
Matsuyama, Ehime, Japan, 791-0280
- NHO Shikoku Cancer Center
-
-
Fukuoka
-
Fukuoka, Fukuoka, Japan, 811-1395
- NHO Kyushu Cancer Center
-
-
Fukushima
-
Fukushima, Fukushima, Japan, 960-1295
- Fukushima Medical University Hospital
-
-
Hiroshima
-
Hiroshima, Hiroshima, Japan, 730-8518
- Hiroshima City Hiroshima Citizens Hospital
-
-
Hokkaido
-
Sapporo, Hokkaido, Japan, 003-0804
- NHO Hokkaido Cancer Center
-
-
Hyōgo
-
Nishinomiya-shi, Hyōgo, Japan, 663-8501
- Hyogo College of Medicine Hospital
-
-
Kagoshima-ken
-
Kagoshima, Kagoshima-ken, Japan, 892-0833
- Hakuaikai Sagara Hospital
-
-
Kanagawa
-
Isehara, Kanagawa, Japan, 259-1193
- Tokai University Hospital
-
Yokohama, Kanagawa, Japan, 241-8515
- Kanagawa Cancer Center
-
-
Osaka
-
Osaka, Osaka, Japan, 540-0006
- NHO Osaka National Hospital
-
-
Osakasayama-shi
-
Onohigashi, Osakasayama-shi, Japan, 589-8511
- Kindai University Hospital
-
-
Saitama
-
Kitaadachi-gun, Saitama, Japan, 362-0806
- Saitama Cancer Center
-
-
Shizuoka
-
Sunto-gun, Shizuoka, Japan, 411-8777
- Shizuoka Cancer Center
-
-
Tokyo-To
-
Kōtoku, Tokyo-To, Japan, 135-8550
- Cancer Institute Hospital of JFCR
-
Minatoku, Tokyo-To, Japan, 105-8470
- Toranomon Hospital
-
Shinagawa-Ku, Tokyo-To, Japan, 142-8666
- Showa University Hospital
-
-
-
-
-
Innsbruck, Oostenrijk, 6020
- Medizinische Universität Innsbruck
-
Linz, Oostenrijk, 4020
- Kepler Universitätsklinikum
-
Salzburg, Oostenrijk, 5020
- LKH - Universitätsklinikum der PMU Salzburg
-
Vienna, Oostenrijk, 1090
- AKH - Medizinische Universität Wien (4305)
-
Wels, Oostenrijk, 4600
- Klinikum Wels-Grieskirchen GmbH
-
-
-
-
-
Braga, Portugal, 4710-243
- Hospital de Braga
-
Guimarães, Portugal, 4835-044
- Centro Hospitalar do Alto do Ave, EPE
-
Lisbon, Portugal, 1649-035
- Centro Hospitalar de Lisboa Norte, E.P.E. - Hospital de Santa Maria
-
Lisbon, Portugal, 1400-038
- Fundação Champalimaud
-
Matosinhos Municipality, Portugal, 4464-509
- Unidade Local de Saúde de Matosinhos, EPE (Hospital Pedro Hispano)
-
Porto, Portugal, 4200-072
- Instituto Português de Oncologia do Porto Francisco Gentil, EPE
-
Porto, Portugal, 4099-001
- Centro Hospitalar do Porto, E.P.E. - Hospital de Santo António
-
Santa Maria da Feira, Portugal, 4520-211
- Centro Hospitalar de Entre o Douro e Vouga, E.P.E - Hospital de São Sebastião
-
Vila Nova de Gaia, Portugal, 4434-502
- Centro Hospitalar Vila Nova de Gaia/Espinho, E.P.E
-
Vila Real, Portugal, 5000-508
- Centro Hospitalar de Trás-os-Montes e Alto Douro, EPE
-
-
-
-
-
Moscow, Rusland, 115478
- FSBSI "Russian Oncological Scientific Center n.a. N.N. Blokhin"
-
Moscow, Rusland, 143423
- SBIH of Moscow City "Moscow City Oncology Hospital №62" of Moscow Healthcare Departement
-
Yaroslavl, Rusland, 150054
- SBIH of Yaroslavl Region "Regional Clinical Oncological Hospital"
-
-
-
-
-
Barcelona, Spanje, 08036
- Hospital Clinic de Barcelona
-
Barcelona, Spanje, 08035
- Hospital Universitari Vall d'Hebron
-
Barcelona, Spanje, 08023
- Hospital Quironsalud Barcelona
-
Barcelona, Spanje, 08003
- Hospital del Mar
-
Madrid, Spanje, 28034
- Hospital Universitario Ramon y Cajal
-
Madrid, Spanje, 28040
- Hospital Universitario Clinico San Carlos
-
Madrid, Spanje, 28034
- Hospital Ruber Internacional
-
Madrid, Spanje, 28033
- MD Anderson Cancer Centre
-
Málaga, Spanje, 29010
- Hospital Clinico Universitario Virgen de la Victoria
-
Seville, Spanje, 41009
- Hospital Universitario Virgen Macarena
-
Seville, Spanje, 41013
- Hospital Universitario Virgen del Rocio
-
Valencia, Spanje, 46014
- Hospital General Universitario de Valencia
-
Valencia, Spanje, 46009
- Instituto Valenciano de Oncologia IVO
-
-
Barcelona
-
L'Hospitalet de Llobregat, Barcelona, Spanje, 08908
- ICO l'Hospitalet - Hospital Duran i Reynals
-
-
Guipuzcoa
-
San Sebastián, Guipuzcoa, Spanje, 20014
- Hospital Universitario Donostia
-
-
La Coruña
-
A Coruña, La Coruña, Spanje, 15006
- Complejo Hospitalario Universitario A Coruña
-
-
Tenerife
-
San Cristóbal de La Laguna, Tenerife, Spanje, 38320
- Hospital Universitario de Canarias
-
-
Vizcaya
-
Bilbao, Vizcaya, Spanje, 48013
- Hospital de Basurto
-
-
-
-
-
Kaohsiung City, Taiwan, 807
- Kaohsiung Medical University Chung-Ho Memorial Hospital
-
Tainan, Taiwan, 704
- National Cheng Kung University Hospital
-
Taipei, Taiwan, 100
- National Taiwan University Hospital
-
-
-
-
Cornwall
-
Truro, Cornwall, Verenigd Koninkrijk, TR1 3LJ
- Royal Cornwall Hospital
-
-
Greater London
-
London, Greater London, Verenigd Koninkrijk, NW3 2QG
- Royal Free Hospital
-
London, Greater London, Verenigd Koninkrijk, EC1M 6BQ
- Queen Mary University of London
-
London, Greater London, Verenigd Koninkrijk, NW1 2PG
- University College London Hospitals
-
-
Lothian Region
-
Edinburgh, Lothian Region, Verenigd Koninkrijk, EH4 2XU
- Western General Hospital
-
-
Nottinghamshire
-
Nottingham, Nottinghamshire, Verenigd Koninkrijk, NG5 1PB
- Nottingham University Hospitals City Campus
-
-
Surrey
-
Guildford, Surrey, Verenigd Koninkrijk, GU2 7XX
- Royal Surrey County Hospital
-
-
-
-
Arizona
-
Chandler, Arizona, Verenigde Staten, 85224
- Ironwood Cancer & Research Centers - Chandler II
-
Gilbert, Arizona, Verenigde Staten, 85234
- Banner MD Anderson Cancer Center
-
Goodyear, Arizona, Verenigde Staten, 85338
- Cancer Treatment Centers of America at Western Regional Medical Center
-
-
California
-
Los Angeles, California, Verenigde Staten, 90095
- UCLA School of Medicine
-
Palo Alto, California, Verenigde Staten, 94305
- Stanford Cancer Institute
-
Redondo Beach, California, Verenigde Staten, 90277
- Cancer Care Associates Medical Group, Inc. TORI
-
San Francisco, California, Verenigde Staten, 94158
- University of California at San Francisco (PARENT)
-
-
Connecticut
-
Norwich, Connecticut, Verenigde Staten, 06360
- Eastern Connecticut Hematology/Oncology Assoc.
-
-
Delaware
-
Newark, Delaware, Verenigde Staten, 19713
- Christiana Care Health Services, Inc.
-
-
Florida
-
Boca Raton, Florida, Verenigde Staten, 33426
- Sylvester Comprehensive Cancer Center - Deerfield Beach
-
Fort Myers, Florida, Verenigde Staten, 33916
- Florida Cancer Specialists (South Region)
-
Hollywood, Florida, Verenigde Staten, 33021
- Memorial Healthcare System MRH Cancer Center
-
Orlando, Florida, Verenigde Staten, 32806
- Orlando Health, Inc.
-
Tampa, Florida, Verenigde Staten, 33139
- Moffitt Cancer Center -Tampa
-
-
Georgia
-
Newnan, Georgia, Verenigde Staten, 30263
- Cancer Treatment Centers of America-Georgia
-
-
Illinois
-
Chicago, Illinois, Verenigde Staten, 60637
- University of Chicago Medical Center
-
Zion, Illinois, Verenigde Staten, 60099
- Cancer Treatment Centers of America
-
-
Kansas
-
Wichita, Kansas, Verenigde Staten, 67214
- Cancer Center of Kansas
-
-
Louisiana
-
New Orleans, Louisiana, Verenigde Staten, 70115
- Touro Infirmary
-
-
Massachusetts
-
Boston, Massachusetts, Verenigde Staten, 02215
- Dana-Farber Cancer Institute
-
-
Michigan
-
Detroit, Michigan, Verenigde Staten, 48202
- Henry Ford Hospital
-
-
Missouri
-
Kansas City, Missouri, Verenigde Staten, 64111
- Saint Luke's Hospital of Kansas City
-
-
New Jersey
-
Livingston, New Jersey, Verenigde Staten, 07039
- Saint Barnabas Medical Center
-
-
New York
-
New York, New York, Verenigde Staten, 10016
- New York University Medical Center
-
New York, New York, Verenigde Staten, 10065
- Memorial Sloan Kettering Hospital
-
New York, New York, Verenigde Staten, 10065
- Weill Cornell Medicine Breast Center
-
-
Ohio
-
Cleveland, Ohio, Verenigde Staten, 44195
- The Cleveland Clinic Foundation
-
-
Oregon
-
Portland, Oregon, Verenigde Staten, 97239
- Oregon Health & Science University
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Verenigde Staten, 15212
- Allegheny General Hospital
-
Pittsburgh, Pennsylvania, Verenigde Staten, 15219
- University of Pittsburgh Medical Center Health System
-
-
South Carolina
-
Greenville, South Carolina, Verenigde Staten, 29601
- St Francis Hospital
-
-
Tennessee
-
Knoxville, Tennessee, Verenigde Staten, 37909
- Brig Center for Cancer Care and Survivorship
-
Memphis, Tennessee, Verenigde Staten, 38120
- Baptist Cancer Center
-
Nashville, Tennessee, Verenigde Staten, 37201
- Tennessee Oncology - Skyline Satellite
-
-
Texas
-
Dallas, Texas, Verenigde Staten, 75234
- BloomTrials Clinical Research, LLC
-
Houston, Texas, Verenigde Staten, 77030
- The Methodist Hospital Research Institute
-
Houston, Texas, Verenigde Staten, 77030
- University of Texas M. D. Anderson Cancer Center - Investigational Cancer Therapeutics
-
-
Virginia
-
Fairfax, Virginia, Verenigde Staten, 22031
- Virginia Cancer Specialists
-
-
-
-
-
Daegu, Zuid -Korea, 41404
- Kyungpook National University Chilgok Hospital
-
Seoul, Zuid -Korea, 03080
- Seoul National University Hospital
-
Seoul, Zuid -Korea, 05505
- Asan Medical Center
-
Seoul, Zuid -Korea, 06351
- Samsung Medical Center
-
Seoul, Zuid -Korea, 06591
- The Catholic University of Korea, Seoul St. Mary's Hospital
-
Seoul, Zuid -Korea, 120-752
- Severance Hospital, Yonsei University Health System
-
-
Gyeonggi-do
-
Goyang-si, Gyeonggi-do, Zuid -Korea, 10408
- National Cancer Center
-
Incheon, Gyeonggi-do, Zuid -Korea, 22332
- Inha University Hospital
-
Seongnam-si, Gyeonggi-do, Zuid -Korea, 13620
- Seoul National University Bundang Hospital
-
Suwon, Gyeonggi-do, Zuid -Korea, 16499
- Ajou University Hospital
-
-
North Chungcheong
-
Cheongju-si, North Chungcheong, Zuid -Korea, 361-711
- Chungbuk National University Hospital
-
-
-
-
-
Solna, Zweden, 17176
- Karolinska universitetssjukhuset - Solna
-
Sundsvall, Zweden, 85186
- Länssjukhuset Sundsvall-Härnösand
-
Uppsala, Zweden, 75185
- Akademiska Sjukhuset
-
-
-
-
-
Aarau, Zwitserland, 5000
- Hirslanden Medical Center
-
Basel, Zwitserland, 4031
- Universitaetsspital Basel
-
Chur, Zwitserland, 7000
- Kantonsspital Graubuenden
-
Lausanne, Zwitserland, 1011
- Centre Hospitalier Universitaire Vaudois
-
Sankt Gallen, Zwitserland, 9007
- Kantonsspital St. Gallen
-
Winterthur, Zwitserland, 8401
- Kantonsspital Winterthur
-
Zurich, Zwitserland, 8091
- Universitaetsspital Zuerich
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
-
Is the age of majority in their country
-
Has pathologically documented breast cancer that:
- Is unresectable or metastatic
- Has low-HER2 expression defined as IHC 2+/ISH- or IHC 1+ (ISH- or untested)
- Is HR-positive or HR-negative
- Has progressed on, and would no longer benefit from, endocrine therapy
- Has been treated with 1 to 2 prior lines of chemotherapy/adjuvant in the recurrent or metastatic setting
- Was never previously HER2-positive (ICH 3+ or ISH+) on prior pathology testing (per American Society of Clinical Oncology-College of American Pathologists [ASCO-CAP] guidelines)
-
Has documented radiologic progression (during or after most recent treatment)
-
Has adequate archival tumor samples available or is wiling to provide fresh biopsies prior to randomization for:
- assessment of HER2 status
- assessment of post-treatment status
-
Has at least 1 measurable lesion per Response Evaluation Criteria In Solid Tumors 1.1
-
Has protocol-defined adequate cardiac, bone marrow, renal, hepatic and blood clotting functions
-
Male and female participants of reproductive/childbearing potential, agrees to follow instructions for method(s) of contraception and agrees to avoid preserving ova or sperm for at least 4.5 months after treatment (or longer, per locally approved labels)
Exclusion Criteria:
- Is ineligible for all options in the physician's choice arm
- Has breast cancer ever assessed with high-HER2 expression
- Has previously been treated with any anti-HER2 therapy, including an antibody drug conjugate
- Has uncontrolled or significant cardiovascular disease
- Has spinal cord compression or clinically active central nervous system metastases
- Has history of (noninfectious) interstitial lung disease (ILD)/pneumonitis that required steroids, has current ILD/pneumonitis, or suspected ILD/pneumonitis that cannot be ruled out by imaging at screening
- Has any medical history or condition that per protocol or in the opinion of the investigator is inappropriate for the study
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Trastuzumab deruxtecan
HER2-low, unresectable, and/or metastatic breast cancer participants previously treated with chemotherapy randomized to DS8201a |
DS-8201a is a lyophilized powder reconstituted into a sterile aqueous solution (100 mg/5 mL) to be administered intravenously
Andere namen:
|
|
Actieve vergelijker: Physician's Choice
HER2-low, unresectable, and/or metastatic breast cancer participants previously treated with chemotherapy randomized to Physician's choice from the following options:
|
Administered according to label, as one option for Physician's Choice (determined before randomization) Administered according to label, as one option for Physician's Choice (determined before randomization) Administered according to label, as one option for Physician's Choice (determined before randomization) Administered according to label, as one option for Physician's Choice (determined before randomization) Administered according to label, as one option for Physician's Choice (determined before randomization) |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Progression-free Survival (PFS) Based on Blinded Independent Central Review (BICR) in the Hormone Receptor-Positive Cohort in Participants With HER2-low Breast Cancer
Tijdsspanne: From the date of randomization to the earliest date of the first objective documentation of radiographic disease progression or death due to any cause, up to approximately 3 years
|
Progression-free survival (PFS), defined as at least a 20% increase in the sum of diameters of target lesions, was assessed from the date of randomization to the date of the first radiographic disease progression or death due to any cause, whichever came first. PFS was based on blinded independent central review (BICR) in the hormone receptor-positive cohort according to modified Response Evaluation Criteria in Solid Tumors (mRECIST) version 1.1. Median PFS was from Kaplan-Meier analysis. Confidence interval for median was computed using the Brookmeyer-Crowley method. |
From the date of randomization to the earliest date of the first objective documentation of radiographic disease progression or death due to any cause, up to approximately 3 years
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Aantal totale overlevingsgebeurtenissen (sterfgevallen)
Tijdsspanne: Vanaf de datum van randomisatie tot de datum van overlijden door welke oorzaak dan ook, tot ongeveer 3 jaar
|
Vanaf de datum van randomisatie tot de datum van overlijden door welke oorzaak dan ook, tot ongeveer 3 jaar
|
|
|
Progression-free Survival (PFS) Based on Blinded Independent Central Review (BICR) in Participants With HER2-low Breast Cancer (All Patients) Regardless of Hormone Receptor Status
Tijdsspanne: From the date of randomization to the earliest date of the first objective documentation of radiographic disease progression or death due to any cause, up to approximately 3 years
|
Progression-free survival (PFS), defined as at least a 20% increase in the sum of diameters of target lesions, was assessed from the date of randomization to the date of the first radiographic disease progression or death due to any cause, whichever came first. PFS was based on blinded independent central review (BICR) according to modified Response Evaluation Criteria in Solid Tumors (mRECIST) version 1.1. Median PFS was from Kaplan-Meier analysis. Confidence interval for median was computed using the Brookmeyer-Crowley method. |
From the date of randomization to the earliest date of the first objective documentation of radiographic disease progression or death due to any cause, up to approximately 3 years
|
|
Progression-free Survival Based on Investigator Assessment in the Hormone Receptor-Positive Cohort in Participants With HER2-low Breast Cancer
Tijdsspanne: From the date of randomization to the earliest date of the first objective documentation of radiographic disease progression or death due to any cause, up to approximately 3 years
|
Progression-free survival (PFS), defined as at least a 20% increase in the sum of diameters of target lesions, was assessed from the date of randomization to the date of the first radiographic disease progression or death due to any cause, whichever came first. PFS was based on investigator assessment in the hormone receptor-positive cohort according to modified Response Evaluation Criteria in Solid Tumors (mRECIST) version 1.1. Median PFS was from Kaplan-Meier analysis. Confidence interval for median was computed using the Brookmeyer-Crowley method. |
From the date of randomization to the earliest date of the first objective documentation of radiographic disease progression or death due to any cause, up to approximately 3 years
|
|
Progression-free Survival Based on Investigator Assessment in Participants With HER2-low Breast Cancer (All Patients)
Tijdsspanne: From the date of randomization to the earliest date of the first objective documentation of radiographic disease progression or death due to any cause, up to approximately 3 years
|
Progression-free survival (PFS), defined as at least a 20% increase in the sum of diameters of target lesions, was assessed from the date of randomization to the date of the first radiographic disease progression or death due to any cause, whichever came first. PFS was based on investigator assessment according to modified Response Evaluation Criteria in Solid Tumors (mRECIST) version 1.1. Median PFS was from Kaplan-Meier analysis. Confidence interval for median was computed using the Brookmeyer-Crowley method. |
From the date of randomization to the earliest date of the first objective documentation of radiographic disease progression or death due to any cause, up to approximately 3 years
|
|
Overall Survival (OS) in the Hormone Receptor-Positive Cohort in Participants With HER2-low Breast Cancer
Tijdsspanne: From the date of randomization up to the date of death due to any cause, up to approximately 3 years
|
Overall survival (OS) was defined as the time from the date of randomization to the date of death due to any cause. If there was no death reported for a participant before the data cutoff for OS analysis, OS was censored at the last contact date at which the participant was known to be alive. |
From the date of randomization up to the date of death due to any cause, up to approximately 3 years
|
|
Overall Survival (OS) in All Patients
Tijdsspanne: From the date of randomization up to the date of death due to any cause, up to approximately 3 years
|
Overall survival (OS) was defined as the time from the date of randomization to the date of death due to any cause. If there was no death reported for a participant before the data cutoff for OS analysis, OS was censored at the last contact date at which the participant was known to be alive. |
From the date of randomization up to the date of death due to any cause, up to approximately 3 years
|
|
Best Overall Response and Confirmed Objective Response Rate (ORR) in the Hormone Receptor-Positive Cohort in Participants With HER2-low Breast Cancer
Tijdsspanne: From screening and every 6 weeks up to withdrawal of subject consent, progressive disease (PD), or unacceptable toxicity, up to approximately 3 years
|
Best overall response rate and confirmed objective response rate (ORR) were assessed by blinded independent central review (BICR) and investigator assessment. Complete response (CR) was defined as a disappearance of all target lesions, partial response (PR) was defined as at least a 30% decrease in the sum of diameters of target lesions, and stable disease (SD) was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD; at least a 20% increase in the sum of diameters of target lesions. Confirmed ORR was defined as the number of participants with complete and partial responses and confirmed by a second assessment. |
From screening and every 6 weeks up to withdrawal of subject consent, progressive disease (PD), or unacceptable toxicity, up to approximately 3 years
|
|
Best Overall Response and Confirmed Objective Response Rate (ORR) in Participants With HER2-low Breast Cancer (All Patients)
Tijdsspanne: From screening and every 6 weeks up to withdrawal of subject consent, progressive disease (PD), or unacceptable toxicity, up to approximately 3 years
|
Best overall response rate and confirmed objective response rate (ORR) were assessed by blinded independent central review (BICR) and investigator assessment. Complete response (CR) was defined as a disappearance of all target lesions, partial response (PR) was defined as at least a 30% decrease in the sum of diameters of target lesions, and stable disease (SD) was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD; at least a 20% increase in the sum of diameters of target lesions. Confirmed ORR was defined as the number of participants with complete and partial responses and confirmed by a second assessment. |
From screening and every 6 weeks up to withdrawal of subject consent, progressive disease (PD), or unacceptable toxicity, up to approximately 3 years
|
|
Duration of Response in the Hormone Receptor-Positive Cohort in Participants With HER2-low Breast Cancer
Tijdsspanne: From the date of the first documented objective response (CR or PR) to the first documented disease progression or death, whichever occurs first, up to approximately 3 years
|
Duration of Response (DoR) is defined as the date of the first documented objective response (complete response [CR] or partial response [PR]) to the first documented disease progression or death, whichever occurs first. DoR was based on blinded independent central review (BICR) and investigator assessment. Median was from Kaplan-Meier estimate. Confidence interval for median was computed using the Brookmeyer-Crowley method. |
From the date of the first documented objective response (CR or PR) to the first documented disease progression or death, whichever occurs first, up to approximately 3 years
|
|
Duration of Response in Participants With HER2-low Breast Cancer (All Patients)
Tijdsspanne: From the date of the first documented objective response (CR or PR) to the first documented disease progression or death, whichever occurs first, up to approximately 3 years
|
Duration of Response (DoR) is defined as the date of the first documented objective response (complete response [CR] or partial response [PR]) to the first documented disease progression or death, whichever occurs first. DoR was based on blinded independent central review (BICR) and investigator assessment. Median was from Kaplan-Meier estimate. Confidence interval for median was computed using the Brookmeyer-Crowley method. |
From the date of the first documented objective response (CR or PR) to the first documented disease progression or death, whichever occurs first, up to approximately 3 years
|
Andere uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
All-Cause Mortality
Tijdsspanne: From the date of randomization up to the date of death due to any cause, up to approximately 3 years
|
All-cause mortality is defined as all anticipated and unanticipated deaths due to any cause, with the number and frequency of such events by arm or comparison group of the clinical study. |
From the date of randomization up to the date of death due to any cause, up to approximately 3 years
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Studie directeur: Global Clinical Leader, Daiichi Sankyo
Publicaties en nuttige links
Algemene publicaties
- Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E, Tsurutani J, Ueno NT, Prat A, Chae YS, Lee KS, Niikura N, Park YH, Xu B, Wang X, Gil-Gil M, Li W, Pierga JY, Im SA, Moore HCF, Rugo HS, Yerushalmi R, Zagouri F, Gombos A, Kim SB, Liu Q, Luo T, Saura C, Schmid P, Sun T, Gambhire D, Yung L, Wang Y, Singh J, Vitazka P, Meinhardt G, Harbeck N, Cameron DA; DESTINY-Breast04 Trial Investigators. Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer. N Engl J Med. 2022 Jul 7;387(1):9-20. doi: 10.1056/NEJMoa2203690. Epub 2022 Jun 5.
- Jhaveri K, Eli LD, Wildiers H, Hurvitz SA, Guerrero-Zotano A, Unni N, Brufsky A, Park H, Waisman J, Yang ES, Spanggaard I, Reid S, Burkard ME, Vinayak S, Prat A, Arnedos M, Bidard FC, Loi S, Crown J, Bhave M, Piha-Paul SA, Suga JM, Chia S, Saura C, Garcia-Saenz JA, Gambardella V, de Miguel MJ, Gal-Yam EN, Rapael A, Stemmer SM, Ma C, Hanker AB, Ye D, Goldman JW, Bose R, Peterson L, Bell JSK, Frazier A, DiPrimeo D, Wong A, Arteaga CL, Solit DB. Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial. Ann Oncol. 2023 Oct;34(10):885-898. doi: 10.1016/j.annonc.2023.08.003. Epub 2023 Aug 18.
- Ueno NT, Cottone F, Dunton K, Jacot W, Yamashita T, Sohn J, Tokunaga E, Prat A, Tsurutani J, Park YH, Rugo HS, Xu B, Cardoso F, Mitri Z, Mahtani R, Aguilar CO, Xiao F, Harbeck N, Cameron DA, Modi S. Patient-reported outcomes from DESTINY-Breast04: trastuzumab deruxtecan versus physician's choice of chemotherapy in patients with HER2-low mBC. Oncologist. 2025 May 8;30(5):oyaf048. doi: 10.1093/oncolo/oyaf048.
- Yamashita T, Sohn JH, Tokunaga E, Niikura N, Park YH, Lee KS, Chae YS, Xu B, Wang X, Im SA, Li W, Lu YS, Aguilar CO, Nishijima S, Nishiyama Y, Sugihara M, Modi S, Tsurutani J. Trastuzumab deruxtecan versus treatment of physician's choice in previously treated Asian patients with HER2-low unresectable/metastatic breast cancer: subgroup analysis of the DESTINY-Breast04 study. Breast Cancer. 2024 Sep;31(5):858-868. doi: 10.1007/s12282-024-01600-7. Epub 2024 Jun 17.
- Ma R, Shi Y, Yan R, Yin S, Bu H, Huang J. Efficacy and safety of trastuzumab deruxtecan in treating human epidermal growth factor receptor 2-low/positive advanced breast cancer:A meta-analysis of randomized controlled trials. Crit Rev Oncol Hematol. 2024 Apr;196:104305. doi: 10.1016/j.critrevonc.2024.104305. Epub 2024 Mar 3.
- Rugo HS, Crossno CL, Gesthalter YB, Kelley K, Moore HB, Rimawi MF, Westbrook KE, Buys SS. Real-World Perspectives and Practices for Pneumonitis/Interstitial Lung Disease Associated With Trastuzumab Deruxtecan Use in Human Epidermal Growth Factor Receptor 2-Expressing Metastatic Breast Cancer. JCO Oncol Pract. 2023 Aug;19(8):539-546. doi: 10.1200/OP.22.00480. Epub 2023 May 19.
- Narayan P, Dilawari A, Osgood C, Feng Z, Bloomquist E, Pierce WF, Jafri S, Kalavar S, Kondratovich M, Jha P, Ghosh S, Tang S, Pazdur R, Beaver JA, Amiri-Kordestani L. US Food and Drug Administration Approval Summary: Fam-Trastuzumab Deruxtecan-nxki for Human Epidermal Growth Factor Receptor 2-Low Unresectable or Metastatic Breast Cancer. J Clin Oncol. 2023 Apr 10;41(11):2108-2116. doi: 10.1200/JCO.22.02447. Epub 2023 Feb 13.
- Iyengar AR, Downs EP, Mehta S, Rangarajan N, Woo MS, Sredni ST, Donato RD, Simsek S, Wilson DM, Krieser K, Patzke EB, Kyek N, Anderson C, Wagner T, Hipp J, Nassar A, Barman H. HER2-Ultralow: Prevalence, Characteristics, and Treatment Choices Among Advanced Breast Cancer Patients With Tumors Initially Scored as IHC 0. Breast J. 2026;2026(1):e7212120. doi: 10.1155/tbj/7212120.
- Modi S, Jacot W, Iwata H, Park YH, Vidal Losada M, Li W, Tsurutani J, Ueno NT, Zaman K, Prat A, Papazisis K, Rugo HS, Yamashita T, Harbeck N, Im SA, De Laurentiis M, Pierga JY, Wang X, Gombos A, Tokunaga E, Orbegoso Aguilar C, Yung L, Xiao F, Cheng Y, Cameron D. Trastuzumab deruxtecan in HER2-low metastatic breast cancer: long-term survival analysis of the randomized, phase 3 DESTINY-Breast04 trial. Nat Med. 2025 Dec;31(12):4205-4213. doi: 10.1038/s41591-025-03981-4. Epub 2025 Oct 8.
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
- Pathologische processen
- Neoplasmata per site
- Neoplasmata
- Neoplastische processen
- Huidziektes
- Borst ziekten
- Pathologische aandoeningen, tekenen en symptomen
- Huid- en bindweefselaandoeningen
- Borstneoplasmata
- Neoplasma metastase
- Organische chemicaliën
- Heterocyclische verbindingen, 1-ring
- Heterocyclische verbindingen
- Nucleïnezuren, nucleotiden en nucleosiden
- Koolwaterstoffen
- Cycloparaffins
- Koolwaterstoffen, alicyclisch
- Koolwaterstoffen, cyclisch
- Terpenen
- Taxoids
- Cyclodecanes
- Diterpenen
- Deoxycytidine
- Cytidine
- Pyrimidine -nucleosiden
- Pyrimidines
- Nucleosiden
- Uracil
- Pyrimidinonen
- Deoxyribonucleosides
- Fluorouracil
- Capecitabine
- Gemcitabine
- Paclitaxel
- 130-nm albumine-gebonden Paclitaxel
- trastuzumab deruxtecan
- eribuline
Andere studie-ID-nummers
- DS8201-A-U303
- 2018 (Subsidie/contract van de Amerikaanse NIH)
- 2018-003069-33 (EudraCT-nummer)
- 184223 (Register-ID: JAPIC CTI)
- DESTINY-B04 (Andere identificatie: Daiichi Sankyo and AstraZeneca)
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
De-identified individual participant data (IPD) and applicable supporting clinical trial documents may be available upon request at https://vivli.org/. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://vivli.org/ourmember/daiichi-sankyo/
IPD-tijdsbestek voor delen
Studies for which the medicine and indication have received European Union (EU) and United States (US), and/or Japan (JP) marketing approval on or after 01 January 2014 or by the US or EU or JP Health Authorities when regulatory submissions in all regions are not planned and after the primary study results have been accepted for publication.
IPD-toegangscriteria voor delen
Formal request from qualified scientific and medical researchers on IPD and clinical study documents from clinical trials supporting products submitted and licensed in the United States, the European Union and/or Japan from 01 January 2014 and beyond for the purpose of conducting legitimate research. This must be consistent with the principle of safeguarding study participants' privacy and consistent with provision of informed consent.
IPD delen Ondersteunend informatietype
- LEERPROTOCOOL
- SAP
- ICF
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .